NETWORK-BASED ANALYSIS OF PROTAC COMPOUNDS TARGETING CDK4/6 IN BREAST CANCER: IDENTIFICATION OF GENE INTERACTIONS AND THERAPEUTIC INSIGHTS

Öz

Cancer is a major disease characterized by rapid and uncontrolled cell growth and proliferation, affecting a large population worldwide. A significant portion of cancer research today involves network analysis. In this study, the gene targets of 8-Cyclopentyl-2-(4-piperazin-1-ylanilino) pteridin-7-one (CPPP-7-one) and the PROTAC CDK4/6 degrader (PROTAC-CDK4/6i) were identified, and their shared targets with breast cancer-related genes were examined. Additionally, protein-protein interactions (PPI) involving the gene targets of these compounds were mapped. The analysis revealed that CDK4 is a common gene target between breast cancer and the CPPP-7-one compound. In contrast, GRM2, the sole gene target of the PROTAC CDK4/6 degrader, did not overlap with any breast cancer-related genes. These findings suggest that CPPP-7-one may play a significant role in cyclin and cyclin-dependent kinase activities, particularly in regulating cell cycle checkpoints, and therefore warrants further investigation. Furthermore, the isolated nature of PROTAC CDK4/6i's target from core cell cycle proteins indicates that it may influence distinct intracellular mechanisms.

Anahtar Kelimeler

• Breast Cancer
• PPI network analysis
• CDK
• PROTAC

MEME KANSERİNDE CDK4/6'YI HEDEFLEYEN PROTAC BİLEŞENLERİNİN AĞ TABANLI ANALİZİ: GEN ETKİLEŞİMLERİNİN BELİRLENMESİ VE TERAPÖTİK ÖNGÖRÜLER

Öz

Kanser hızlı ve kontrolsüz hücre büyümesi ve çoğalması olarak tanımlanan ve çok geniş kitleleri etkileyen önemli bir hastalıktır. Kanser üzerinde yapılan araştırmaların önemli bir bölümünü network analizleri oluşturmaktadır. Yapılan bu çalışmada 8-Cyclopentyl-2-(4-piperazin-1-ylanilino) pteridin-7-one (CPPP-7-one) ve PROTAC CDK4/6 degrader (PROTAC-CDK4/6i) bileşenlerinin gen hedefleri bulunmuş, meme kanseri hedefleri ile ortak genleri tespit edilmiştir. Ayrıca bileşenlerin gen hedeflerini protein-protein (PPI) etkileşimleri bulunmuştur. Yapılan bu analizlerin sonucunda meme kanseri ile CPPP-7-one bileşiğinin CDK4 geni ortak olarak bulunmuştur. PROTAC CDK4/6 degrader bileşiğinin GRM2 gen tek gen hedefi meme kanseri ile ortak gen içermemektedir. Sonuç olarak CPPP-7-one bileşiğinin özellikle siklinler ve siklin bağımlı kinaz aktivitelerinde etkili olduğu, hücre döngüsü kontrol noktalarını etkilediği için daha geniş çapta araştırılmasına ihityaç vardır. PROTAC CDK4/6 degrader bileşiğinin de hücre döngüsü proteinlerinden izole olması hücre içinde daha farklı mekanizmaları etkilediğini göstermektedir.

Anahtar Kelimeler

• Meme kanseri
• PPI network analizleri
• CDK
• PROTAC

Kaynakça

1. Bolton EE, Chen J, Kim S, Han L, He S, Shi W, Simonyan V, Sun Y, Thiessen PA, Wang J, Yu B, Zhang J, Bryant SH. PubChem3D: A new resource for scientists. J Cheminform. 2011 Sep 20; 3(1):32. [PubMed PMID: 21933373] https://doi.org/10.1186/1758-2946-3-32
2. Bondeson DP, et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat Chem Biol. 2015. Burslem GM, Crews CM. Proteolysis-targeting chimeras as therapeutics and tools for biological discovery. Cell. 2020.
3. Daina, A., & Zoete, V. (2024). Testing the predictive power of reverse screening to infer drug targets, with the help of machine learning. Communications chemistry, 7(1), 105. https://doi.org/10.1038/s42004-024-01179-2 Das J, Gayvert KM, Bunea F, et al. ENCAPP: elastic-net-based prognosis prediction and biomarker discovery for human cancers. BMC Genomics 2015; 16:263.
4. Gfeller, D., Michielin, O., & Zoete, V. (2013). Shaping the interaction landscape of bioactive molecules. Bioinformatics, 29(23), 3073-3079.
5. Hu, Y., Gao, J., Wang, M., & Li, M. (2021). Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer. Cancer management and research, 13, 5223–5237. https://doi.org/10.2147/CMAR.S310649
6. Joung, J. G., Kim, D., Lee, S. Y., Kang, H. J., & Kim, J. H. (2014). Integrated analysis of microRNA-target interactions with clinical outcomes for cancers. BMC medical genomics, 7 Suppl 1(Suppl 1), S10. https://doi.org/10.1186/1755-8794-7-S1-S10
7. Kim, S., Chen, J., Cheng, T., Gindulyte, A., He, J., He, S., Li, Q., Shoemaker, B. A., Thiessen, P. A., Yu, B., Zaslavsky, L., Zhang, J., & Bolton, E. E. (2025). PubChem 2025 update. Nucleic Acids Res., 53(D1), D1516–D1525. https://doi.org/10.1093/nar/gkae1059
8. Li, R., Liu, M., Yang, Z., Li, J., Gao, Y., & Tan, R. (2022). Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future. Molecules (Basel, Switzerland), 27(24), 8828. https://doi.org/10.3390/molecules27248828

9. Malumbres, M., & Barbacid, M. (2009). Cell cycle, CDKs and cancer: a changing paradigm. Nature reviews. Cancer, 9(3), 153–166. https://doi.org/10.1038/nrc2602
10. Murphy C. G. (2019). The Role of CDK4/6 Inhibitors in Breast Cancer. Current treatment options in oncology, 20(6), 52. https://doi.org/10.1007/s11864-019-0651-4
11. Oliveros, J.C. (2007-2015) Venny. An interactive tool for comparing lists with Venn's diagrams. https://bioinfogp.cnb.csic.es/tools/venny/index.html
12. Ono, K., Fong, D., Gao, C., Churas, C., Pillich, R., Lenkiewicz, J., Pratt, D., Pico, A. R., Hanspers, K., Xin, Y., Morris, J., Kucera, M., Franz, M., Lopes, C., Bader, G., Ideker, T., & Chen, J. (2025). Cytoscape Web: bringing network biology to the browser. Nucleic acids research, gkaf365. Advance online publication. https://doi.org/10.1093/nar/gkaf365
13. Ozturk, K., Dow, M., Carlin, D. E., Bejar, R., & Carter, H. (2018). The Emerging Potential for Network Analysis to Inform Precision Cancer Medicine. Journal of molecular biology, 430(18 Pt A), 2875–2899. https://doi.org/10.1016/j.jmb.2018.06.016
14. Patel, V. N., Gokulrangan, G., Chowdhury, S. A., Chen, Y., Sloan, A. E., Koyutürk, M., Barnholtz-Sloan, J., & Chance, M. R. (2013). Network signatures of survival in glioblastoma multiforme. PLoS computational biology, 9(9), e1003237. https://doi.org/10.1371/journal.pcbi.1003237
15. Piñero, J., Bravo, À., Queralt-Rosinach, N., Gutiérrez-Sacristán, A., Deu-Pons, J., Centeno, E., García-García, J., Sanz, F., & Furlong, L. I. (2017). DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants. Nucleic acids research, 45(D1), D833–D839. https://doi.org/10.1093/nar/gkw943
16. Qiu, J., Bai, X., Zhang, W., Ma, M., Wang, W., Liang, Y., Wang, H., Tian, J., & Yu, P. (2022). LPM3770277, a Potent Novel CDK4/6 Degrader, Exerts Antitumor Effect Against Triple-Negative Breast Cancer. Frontiers in pharmacology, 13, 853993. https://doi.org/10.3389/fphar.2022.853993
17. Safran, M., Rosen, N., Twik, M., BarShir, R., Stein, T. I., Dahary, D., ... & Lancet, D. (2021). The genecards suite. Practical guide to life science databases, 27-56.
18. Sakamoto KM, et al. Protacs: chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation. Proc Natl Acad Sci USA. 2001.
19. Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., & Ideker, T. (2003). Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome research, 13(11), 2498–2504. https://doi.org/10.1101/gr.1239303
20. Stelzer, G., Rosen, N., Plaschkes, I., Zimmerman, S., Twik, M., Fishilevich, S., Stein, T. I., Nudel, R., Lieder, I., Mazor, Y., Kaplan, S., Dahary, D., Warshawsky, D., Guan-Golan, Y., Kohn, A., Rappaport, N., Safran, M., & Lancet, D. (2016). The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses. Current protocols in bioinformatics, 54, 1.30.1–1.30.33. https://doi.org/10.1002/cpbi.5
21. Sung, H. et al. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249. https://doi.org/10.3322/caac.21660
22. Szklarczyk, D., Kirsch, R., Koutrouli, M., Nastou, K., Mehryary, F., Hachilif, R., Gable, A. L., Fang, T., Doncheva, N. T., Pyysalo, S., Bork, P., Jensen, L. J., & von Mering, C. (2023). The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic acids research, 51(D1), D638–D646. https://doi.org/10.1093/nar/gkac1000
23. Wu, Z., Xia, F., & Lin, R. (2024). Global burden of cancer and associated risk factors in 204 countries and territories, 1980-2021: a systematic analysis for the GBD 2021. Journal of hematology & oncology, 17(1), 119. https://doi.org/10.1186/s13045-024-01640-8
24. Zhang, F., Ren, C., Lau, K. K., Zheng, Z., Lu, G., Yi, Z., Zhao, Y., Su, F., Zhang, S., Zhang, B., Sobie, E. A., Zhang, W., & Walsh, M. J. (2016). A network medicine approach to build a comprehensive atlas for the prognosis of human cancer. Briefings in bioinformatics, 17(6), 1044–1059. https://doi.org/10.1093/bib/bbw076
25. Zhang, L., Fan, S., Vera, J., & Lai, X. (2022). A network medicine approach for identifying diagnostic and prognostic biomarkers and exploring drug repurposing in human cancer. Computational and structural biotechnology journal, 21, 34–45. https://doi.org/10.1016/j.csbj.2022.11.037
26. Zhang, W., Chien, J., Yong, J., & Kuang, R. (2017). Network-based machine learning and graph theory algorithms for precision oncology. NPJ precision oncology, 1(1), 25. https://doi.org/10.1038/s41698-017-0029-7
27. Zhou, Y., Zhou, B., Pache, L., Chang, M., Khodabakhshi, A. H., Tanaseichuk, O., Benner, C., & Chanda, S. K. (2019). Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nature communications, 10(1), 1523. https://doi.org/10.1038/s41467-019-09234-6